US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Conduit Pharmaceuticals

News headline image
Conduit to Change Name to CDT Equity Inc.
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Engages Consultant to Explore Cryptocurrency Reserve Strategy
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Announces Leadership Changes
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Progresses Phase II of its AI Initiative with Sarborg
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune Pipeline
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT
News headline image
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders
From Conduit Pharmaceuticals
Via GlobeNewswire
Tickers CDT